Table 2 Treatment-related acute adverse events
Patients, no. (%) | ||||||||
|---|---|---|---|---|---|---|---|---|
UTI group (n = 89) | Control group (n = 90) | |||||||
Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
Any acute adverse eventa | 9 (10.1) | 58 (65.2) | 21 (23.6) | 1 (1.1) | 8 (8.9) | 58 (64.4) | 24 (26.7) | 0 |
Hematologic toxic effects | ||||||||
Leukopenia | 15 (16.8) | 43 (48.3) | 13 (14.6) | 1 (1.1) | 14 (15.5) | 45 (50.0) | 13 (14.4) | 0 |
Neutropenia | 19 (21.3) | 21 (23.5) | 4 (4.4) | 0 | 20 (22.2) | 13 (14.4) | 8 (8.8) | 0 |
Anemia | 29 (32.5) | 9 (10.1) | 2 (2.2) | 0 | 20 (22.2) | 6 (6.7) | 0 | 0 |
Thrombocytopenia | 7 (7.8) | 3 (3.4) | 1 (1.1) | 0 | 7 (7.8) | 1 (1.1) | 1 (1.1) | 0 |
Nonhematologic toxic effects | ||||||||
Nausea and vomiting | 77 (86.5) | 12 (13.4) | 0 | 0 | 76 (84.4) | 13 (14.4) | 1 (1.1) | 0 |
Hepatotoxicity | 8 (8.9) | 2 (2.2) | 1 (1.1) | 0 | 7 (7.8) | 4 (4.4) | 1 (1.1) | 0 |
Nephrotoxicity | 2 (2.2) | 3 (3.4) | 0 | 0 | 5 (5.6) | 0 | 0 | 0 |
Dry mouth | 32 (35.9) | 45 (50.5) | 8 (8.9) | 0 | 31 (34.4) | 46 (51.1) | 8 (8.9) | 0 |
Auditory/hearing | 32 (35.9) | 25 (28.0) | 1 (1.1) | 0 | 37 (41.1) | 19 (21.1) | 6 (6.7) | 0 |
Skin/neck tissue damage | 53 (59.5) | 8 (9.0) | 0 | 0 | 48 (53.3) | 3 (3.3) | 0 | 0 |
